Monday, August 19, 2013
is developing a mAb that directly targets ceramide molecules in the cell
membrane, blocking their ability to induce apoptosis in tissues subjected to
stressors such as radiation. But the mAb doesn't impair normal ceramide
synthesis or metabolism, meaning it may be safer than other ceramide-targeting
compounds in development.
The company is pursuing
gastrointestinal acute radiation syndrome (GI ARS), but also sees applications
for preventing stem cell death in cytolytic T cell-mediated autoimmune
diseases like graft-versus-host disease (GvHD).